Crinetics Pharmaceuticals Inc. (CRNX), which reported positive results from its phase III PATHFNDR-1 study last September, is expected to report phase III PATHFNDR-2 study topline data this quarter.
The company's lead drug candidate is Paltusotine, a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist designed for the treatment of acromegaly.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com